Acute graft versus host disease

This study is tracking the safety and effectiveness of the drug JAKAVI (ruxolitinib) in 395 patients with graft-versus-host disease (GVHD), a complication of bone marrow transplants. Researchers are monitoring infections and other side effects in patients receiving the drug in ro…

This study tests whether transplanting a patient's own fecal bacteria can prevent acute graft-versus-host disease (GVHD) after a stem cell transplant. GVHD is a serious condition where donor cells attack the patient's body. The trial will enroll 100 bone marrow transplant patient…

This study tests whether fecal microbiota transplantation (FMT) can safely treat gut graft-versus-host disease (GVHD), a serious complication after stem cell transplants. Researchers will track changes in stool frequency and volume in 50 participants aged 10 to 60. The goal is to…

This study tests a bone marrow transplant from a family donor for children under 21 with severe non-cancer blood disorders like sickle cell disease, bone marrow failure, or immune problems. The goal is to see if the transplant can replace the diseased cells with healthy donor cel…

This study tests whether fecal microbiota transplantation (FMT) can help people with severe gut graft-versus-host disease (GvHD) that doesn't respond to steroids. GvHD is a common and dangerous complication after stem cell transplants, where donor cells attack the patient's body.…

This study tests whether moxibustion, a traditional Chinese medicine technique that involves burning dried mugwort near the skin, can help people with a severe complication of stem cell transplants called graft-versus-host disease (GVHD) that does not respond to steroids. The tri…

This study tests whether adding a new oral drug (ivarmacitinib) to standard medicines can prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant from a female donor who has given birth. About 82 adults with blood cancers will receive t…

This early study tests whether adding special cells from donated umbilical cord blood (called mesenchymal stromal cells) to the drug ruxolitinib can help control severe graft-versus-host disease (GVHD) that hasn't improved with steroids. GVHD is a serious complication where donor…

This phase 2 trial is testing whether adding the drug ruxolitinib to standard steroid treatment can better control severe acute graft-versus-host disease (GVHD), a serious complication after stem cell transplants. The study will enroll 54 people who develop severe GVHD within 100…

This study tests a new treatment made from special stem cells (iMSC) for people with a serious complication after bone marrow transplant called graft-versus-host disease that does not respond to steroids. The treatment aims to control the disease by calming the immune system. Abo…

This study tests a drug called ruxolitinib for treating acute graft-versus-host disease (GVHD), a serious condition where donor cells attack the patient's body after a bone marrow transplant. About 98 adults with moderate to severe GVHD will receive either ruxolitinib alone or wi…

This early-phase trial is testing an experimental drug called AC-003 in 24 adults who have acute graft-versus-host disease (aGVHD) after a stem cell transplant and whose condition has not improved with steroids. The study aims to see if the drug is safe and tolerable, and to get …

This early-stage study tests whether giving patients a fecal transplant (donated stool) along with extra dietary fiber can help treat gut graft versus host disease, a serious complication after a stem cell transplant. About 72 adults who had a stem cell transplant in the past yea…

This study tests whether using stem cells from both a half-matched family donor and a cord blood donor can improve survival without cancer returning. It is for people with certain high-risk blood cancers like leukemia or myelodysplastic syndromes. The approach aims to control the…

This study tests whether adding ruxolitinib to standard steroids works better than steroids alone for grade II acute graft-versus-host disease (GVHD), a common complication after stem cell transplant. About 168 adults who have had a first stem cell transplant for blood cancer and…

This phase 3 trial is testing whether changing the timing of stem cell infusion after a single umbilical cord blood transplant can lower the risk of severe acute graft-versus-host disease (aGVHD) in people with blood cancers. The study will enroll 134 participants who are in remi…

This study tests a drug called gecacitinib (jaktinib) combined with steroids as a first treatment for acute graft-versus-host disease (GVHD), a serious complication after stem cell transplants. About 35 adults who have had a stem cell transplant and develop moderate to severe GVH…

This study tests whether putting healthy donor stool into the gut can help people with severe gut inflammation after a stem cell transplant. The condition, called gastrointestinal graft-versus-host disease, is hard to treat and often deadly. Fifteen patients will receive the stoo…

This study tests a drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant. Fifty adults with blood cancers like leukemia will receive six weekly doses of BPC200…

This study tests a drug called RLS-0071 in 66 hospitalized patients who have severe graft-versus-host disease (GVHD) after a stem cell transplant and did not improve with steroids. The drug is given for 7 to 14 days to see if it is safe and helps control the immune reaction. The …

This study tests the drug ruxolitinib in 36 Chinese adults and teens (12+) who have severe graft-versus-host disease after a stem cell transplant and did not improve with steroids. Participants take ruxolitinib pills daily for up to 56 days. The main goal is to see how many patie…

This program provides early access to the drug ruxolitinib for people with serious or life-threatening conditions like certain blood cancers, severe COVID-19, or graft-versus-host disease. It is for patients who have no other treatment options and cannot join a clinical trial. Th…

This study offers a special way to prepare donor stem cells for children and teens under 22 who need a transplant but lack a perfectly matched sibling donor. The method uses the CliniMACS® system to remove certain immune cells, which may help reduce the risk of graft-versus-host …

This phase 2 trial tests whether a new way of giving anti-thymocyte globulin (ATG) along with standard drugs tacrolimus and methotrexate can prevent acute graft-versus-host disease (GVHD) after a stem cell transplant. The study enrolls 29 adults aged 18-60 with blood cancers who …

This phase 2 trial tests a two-step dosing schedule of anti-thymocyte globulin (ATG) combined with standard drugs (tacrolimus and mini methotrexate) to prevent severe graft-versus-host disease (GVHD) in 56 adults with blood cancers like acute leukemia. Participants receive ATG on…

This study tests whether adding etanercept to the standard drug ruxolitinib can better control severe graft-versus-host disease (GVHD) in people who have had a stem cell transplant. GVHD occurs when donor immune cells attack the recipient's body, and current treatments often fail…

This study tests whether a dental cleaning shortly after a stem cell transplant can prevent chronic graft-versus-host disease (GVHD), a common and serious complication. Researchers will enroll 45 adults receiving a donor stem cell transplant for blood cancer. The goal is to see i…

This study tests whether a dietary supplement called galacto-oligosaccharide (GOS) can prevent acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant. GVHD is a serious complication where donor cells attack the patient's body. The supplement aims to cha…

This study tests whether a computer alert can help doctors remember to prescribe blood-thinning medicine for high-risk patients after they leave the hospital. Blood clots are a serious risk for some hospitalized patients, even after discharge. The trial will include 400 adults ag…

This study is testing a new digital application called SHIFT to see if it can improve sexual health, quality of life, and reduce distress in people who have had a stem cell or bone marrow transplant. The trial will enroll 300 adult survivors who are at least three months post-tra…

This study looks at whether a home-based aerobic and resistance exercise program is feasible for adults with graft-versus-host disease (GVHD) after a stem cell transplant. Participants will either do aerobic and resistance exercises or simple stretching. The goal is to see if exe…

This study aims to learn more about how diseases related to blood clots, the immune system, and blood vessels start and change over time. Researchers will enroll up to 1,000 people aged 5 and older, including those with these conditions, their healthy relatives, and healthy volun…

This study looks for better ways to detect lung inflammation and infections early in people who have received a stem cell transplant from a donor. About 40 participants aged 5 to 70 will get regular lung scans, breathing tests, blood draws, and a procedure where a tube collects f…

This study is testing whether two blood markers, CXCL9 and EASIX, can predict severe acute graft-versus-host disease (GVHD) after a stem cell transplant. Researchers will take blood samples from 100 adult patients 28 days after transplant to see if these markers can spot early si…

This study is testing a tool called B-COMPASS that uses a 22-question survey to predict whether people will follow their prescribed treatments. Researchers will enroll 3100 adults with cardiovascular, endocrine, immune, nerve, cancer, or rare diseases across Europe. The goal is t…

This study is creating a large registry of 800 people receiving biologic medications for immune conditions like autoimmune diseases and primary immune deficiencies. Researchers will collect blood samples and health data to better understand how these treatments work and who respo…

This study looks at 60 people getting a stem cell transplant to see if their autonomic nervous system (which controls things like heart rate and sweating) can help predict a serious complication called graft-versus-host disease (GvHD). Participants will have simple nerve tests be…